<DOC>
	<DOCNO>NCT00937560</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety first-line chemotherapy carboplatin dose-dense weekly paclitaxel plus bevacizumab ( Avastin ) participants epithelial ovarian , fallopian tube , primary peritoneal cancer . Participants receive 6-8 3-week cycle treatment bevacizumab 7.5 mg/kg intravenously ( iv ) Day 1 cycle , paclitaxel 80 mg/m^2 iv day 1 , 8 , 15 cycle , carboplatin iv area curve ( AUC ) 6 day 1 cycle . Following combination chemotherapy , bevacizumab could continue give monotherapy .</brief_summary>
	<brief_title>A Study First Line Treatment With Avastin ( Bevacizumab ) Combination With Carboplatin Weekly Paclitaxel Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria Female patient , â‰¥ 18 year age . Epithelial ovarian , fallopian tube , primary peritoneal cancer . Initial surgery , chemotherapy radiotherapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Exclusion Criteria Nonepithelial tumor . Ovarian tumor low malignant potential . Previous systemic anticancer therapy ovarian cancer . History evidence synchronous primary endometrial cancer . Current recent daily treatment aspirin ( &gt; 325mg/day ) full dose anticoagulant thrombolytic agent therapeutic purpose .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>